EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1995 2015 EMA

13 March 2015

# Science, Medicines, Health:
## Patients at the heart of future innovation

## Conference programme

18 March 2015

East Wintergarden, 43 Bank Street, London E14 5NX, United Kingdom



30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

An agency of the European Union

## Welcome to all participants

When the European Medicines Agency was created 20 years ago, the European Union was a smaller place and European healthcare and its regulatory environment looked vastly different from what we see today. The changing healthcare needs of our patients, advancements in science and medicine, the enlargement of the European Union, and legislative changes have shaped the Agency's growth over the first two decades. From our humble beginnings with just 16 staff members and two committees in 1995, we've now expanded to an Agency with about 900 staff and seven scientific committees supporting 28 Member States to ensure that medicines for people and animals in Europe are safe, effective and of high quality.

Patients have always been at the heart of our work aimed at allowing all European patients to benefit from advancements in science, medicines and health. We remember with some nostalgia the first product to be centrally authorised on 20 October 1995. Today, almost all new and innovative medicines are authorised centrally, resulting in significantly improved access for all European patients.

We have come a long way in many areas. Latest milestones include the establishment of the Pharmacovigilance and Risk Assessment Committee set up in 2012 to better monitor and act upon safety issues around medicines or the landmark policy on the publication of clinical study reports that will enter into force in January 2015.

However, there is no room for complacency as we are confronted with numerous challenges that need to be tackled also on the regulatory front, such as the scourge of chronic diseases including cancers and heart diseases, the global threat of antibiotic resistance and public health emergencies such as Ebola, to name but a few. In addition, there are still diseases for which no treatment is available.

We expect that shifts in healthcare systems and rapid scientific progress will change the way medicines are developed and brought to patients in the future, and regulators will have to respond accordingly. We need to seize new opportunities and address challenges together with all our stakeholders so that we continue to deliver on our mission to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. We therefore see the anniversary conference "**Science, Medicines, Health: Patients at the heart of future innovation**" as an ideal forum to discuss with many of our important stakeholders, how to best support innovation in order to increase public health.

I warmly invite you to join us and our panel of esteemed speakers for what promises to be an exciting and dynamic conference.

Andreas Pott

Deputy Executive Director

# Programme details – Wednesday 18 March 2015

## 10.00 Registration

Please pick up your badge and enjoy refreshments in the meeting room

## 11.00 Welcome and Opening

**Guido Rasi,** Principal Adviser in Charge of Strategy, European Medicines Agency

**Ladislav Miko,** Acting Director General for Health and Food Safety (DG SANTE), European Commission

## 11.15 Congratulatory Speech

**Margaret Hamburg,** Commissioner, US Food and Drug Administration

## 11.30 Keynote Address: What I expect from EMA for the next 5 years

**Elias Zerhouni,** President, Global R&D, Sanofi
*The Innovator's Perspective*

**Sir Mark Walport,** Chief Scientific Adviser to Her Majesty's Government
*The Public Health Perspective*

## 12.30 Lunch break

A finger buffet-style lunch will be served at East Wintergarden

## 13.30 Panel Discussion (Moderator: **Malcolm Rowland**, Professor Emeritus, School of Pharmacy, University of Manchester)

**Yann Le Cam**, Chief Executive Officer, EURORDIS, France
*The Patients' Perspective*

**Carole Longson**, Director, Centre for Health Technology Evaluation, NICE, UK
*The HTAs/Payers' Perspective*

**Andrea Ponti**, Partner, GHO Capital Partners LLP, UK
*The Investor's Perspective*

**Adam Cohen**, Professor of Clinical Pharmacology, University of Leiden, NL
*The Academic's Perspective*

**Tomas Salmonson**, Chair, EMA's Committee for Human Medicinal Products
*The Regulator's Perspective*

**Hans-Georg Eichler**, Senior Medical Officer, European Medicines Agency
*The Regulator's Perspective*

## 15.45 Thank you and Closing

**Sir Kent Woods**, Chair, EMA's Management Board

## Conference secretariat

European Medicines Agency
30 Churchill Place, Canary Wharf
London E14 5EU, United Kingdom
**Telephone** +44 (0) 77 65 858 611
**E-mail** Anniversary@ema.europa.eu
**Website** www.ema.europa.eu

## Conference venue

East Wintergarden
43 Bank Street, Canary Wharf
London E14 5NX, United Kingdom

**Website** http://canarywharf.com/east-wintergarden/